Skip Navigation

BELLUS Health

News
Events & Presentations

Visit us on Twitter
Visit us on LinkedIn

EN
FR

Search:
- EN
- FR
About Us
Pipeline
- Our Pipeline
- Camlipixant (BLU-5937)
Science
- Role of P2X3
- Scientific Publications
Patients
- What is Chronic Cough?
- Clinical Trials
Investors & Media
Careers
- Join Our Team
- Job Opportunities
Visit us on Twitter Visit us on LinkedIn

Site Map

Home
About Us
Pipeline
- Our Pipeline
- Camlipixant (BLU-5937)
Science
- Role of P2X3
- Scientific
  Publications
Patients
- What is Chronic Cough?
- Clinical Trials
Investors
& Media
Careers
- Join Our Team
- Job Opportunities
Risk Factors
Privacy Notice
Legal Disclaimer
Site Map

BELLUS Health, Inc.

275 Armand-Frappier Blvd.
Laval, Quebec H7V 4A7
Canada

F 450 680 4501

E info@bellushealth.com

Visit us on Twitter

Visit us on LinkedIn

BELLUS HEALTH IS A DRUG DEVELOPMENT COMPANY AND OUR PRODUCT CANDIDATES ARE NOT YET COMMERCIALIZED. INVESTING IN OUR COMMON SHARES INVOLVES A SIGNIFICANT AMOUNT OF RISK. REFER TO THE ANNUAL INFORMATION FORM IN THE INVESTOR AND MEDIA SECTION OF THIS WEBSITE OR AT WWW.SEDAR.COM FOR A DESCRIPTION OF RISK FACTORS ASSOCIATED WITH OUR BUSINESS.

Risk Factors
Privacy Notice
Legal Disclaimer
Site Map

©2023 BELLUS Health Inc. All Rights Reserved.

Schema

GSK has completed its acquisition of BELLUS Health.

Continue to Site

View Press Release